Background: IVIVC is usually developed for in vivo absorption when drug dissolution is a rate-limiting step. Two key mechanisms, drug dissolution and permeation, rely on the absorption and thus the bioavailability of the oral solid dosage form. The key parameters influencing dissolution are the physicochemical properties of a substance, such as solubility and the gastrointestinal setting. The dissolution of in vitro drugs will be used as a substitute for in vivo absorption. Objective: The main objective of the study was to identify the physicochemical properties, pharmacokinetics, drug-likeness Methods: Swiss ADME tool was used to find out the in silico properties. Drug release and/or dissolution from the dosage form is the only factor governing drug absorption. In connection to that a potent molecule must meet its target in the body in adequate quantities to be successful as a drug, and remain there in a bioactive state long enough for the required biological events that exist. Drug development provides a comprehensive picture of absorption, distribution, metabolism and excretion (ADME) early these days in the process of discovery, at a time when there are multiple compounds considered, but access to physical samples is limited. Results and Disscussion: In our study which have used as model anticancer drugs Axitinib, Ibrutinib,Icotinib, Nilotinib and Dasatinib were evaluated. Computer simulations represent legitimate alternatives to experiments in that regard. Conclusion: During IVIVC drug development program chemical compound or drug molecules prior do the insilico model for promising analysis for drug development process.
Key words: In silico, IVIVC, SwissADME, solubility, permeability and anticancer agents